Cargando…
Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC)()
PURPOSE: Inflammatory breast cancer (IBC) is arguably the deadliest form of breast cancer due to its rapid onset and highly invasive nature. IBC carries 5- and 10-year disease-free survival rates of ~45% and <20%, respectively. Multiple studies demonstrate that in comparison with conventional bre...
Autores principales: | Joglekar-Javadekar, Madhura, Van Laere, Steven, Bourne, Michael, Moalwi, Manal, Finetti, Pascal, Vermeulen, Peter B., Birnbaum, Daniel, Dirix, Luc Y., Ueno, Naoto, Carter, Monique, Rains, Justin, Ramachandran, Abhijit, Bertucci, Francois, van Golen, Kenneth L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470553/ https://www.ncbi.nlm.nih.gov/pubmed/28609680 http://dx.doi.org/10.1016/j.neo.2017.03.002 |
Ejemplares similares
-
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC
por: Rypens, Charlotte, et al.
Publicado: (2022) -
Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC
por: Iwase, Toshiaki, et al.
Publicado: (2020) -
Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors
por: Bertucci, François, et al.
Publicado: (2021) -
Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10(th) Anniversary Conference
por: Woodward, Wendy A., et al.
Publicado: (2017) -
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015)